Cough in Idiopathic Pulmonary Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

*
Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment

*
Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.

*
In March 2024, US-based Seyltx has finalized an agreement to acquire Algernon Pharmaceuticals' chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

*
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is developing Haduvio Trademark (oral nalbuphine ER) for patients with chronic cough associated with idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. The company announced the start of its Phase 2b CORAL clinical trial, which will assess three doses of Haduvio against a placebo in around 160 IPF patients with chronic cough. This Phase 2b trial follows the successful Phase 2a CANAL trial, which showed a statistically significant 75.1% reduction in daytime cough frequency, representing a 52.5% difference from placebo (p



This release was published on openPR.